Immunologic Factor – Page 46

Gilead’s Strategic Focus: CymaBay Liver Drug, Trodelvy Data, and Long-Acting PrEP in 2023

12 months ago talkbio0Tagged CymaBay, Gilead, liver drug, PREP gene, readouts, Strategic Focus, Trodelvy

Gilead, CymaBay, liver drug, Trodelvy, readouts, long-acting PrEP, 2023, strategic focus.

GSK Files Lawsuit Against Pfizer and BioNTech for Alleged COVID-19 Vaccine Patent Violation

12 months ago talkbio0Tagged BioNTech, COVID19 (disease), infringement, Intellectual Property, Legal patent, Pfizer, SmithKline Beecham, Vaccines

GSK, Pfizer, BioNTech, COVID-19, patent infringement, vaccine, lawsuit, intellectual property

ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment

1 year ago talkbio0Tagged Approved, Carcinoma of urinary bladder, invasive, ImmunityBio, Immunotherapy, Interleukin-15, Malignant Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Superagonist, United States Food and Drug Administration

ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment

AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline

1 year ago talkbio0Tagged AbbVie, Approved, Crohn 's disease, Drops - Drug Form, Humira, Immunology, Inhibitor, J&J, Janus kinase, Physicians ' ranking, Players, Rinvoq, United States Food and Drug Administration

AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor

Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign

1 year ago talkbio0Tagged Commercial Vaccine, Cost-Savings Campaign, Effectiveness, Efficiency, Employee, Evolving, Market, Optimization, Outplacement, restructuring, sanofi, streamlined strategic sales, Structure, Vaccines

Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

1 year ago talkbio0Tagged Clinical, Lesion, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Ocrevus, Relapse, Roche (company)

Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures

Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus

1 year ago talkbio0Tagged Antibodies, Biosciences, Immunoglobulin M, Neoplasms, Partnership, sanofi

Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership

AstraZeneca’s FASENRA Gains FDA Approval for Add-On Maintenance Treatment of Severe Asthma in Children Aged 6-11

1 year ago talkbio0Tagged Age, Approved, AstraZeneca, benralizumab, Child, expansion, Fasenra, Pediatric Label, Severe asthma, United States Food and Drug Administration

AstraZeneca, FASENRA, Benralizumab, Severe Asthma, Pediatric Label Expansion, FDA Approval, Children Aged 6-11

Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials

1 year ago talkbio0Tagged cellular targeting, Collaboration, CureVac, Immune response, Improved, influenza B strains, mRNA flu, Optimization, Vaccines

CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK